Paper30701409
Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.
Ghiaccio V and 3 others. Mol Diagn Ther, 2019. Cited by 20 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges. Papers, record 30701409. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30701409
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Genetic Therapy | Major topic |
| Hemoglobinopathies | Major topic |
| beta-Globins | Major topic |
| Epigenesis, Genetic | |
| Gene Editing | |
| Humans | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 DK090554 | NIDDK NIH HHS | United States | R01DK090554 | PubMed and NIH | NIH RePORTER |
| R01 DK095112 | NIDDK NIH HHS | United States | R01DK095112 | PubMed and NIH | NIH RePORTER |
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21,881,051 | Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. | Blood | 2011 | https://conductscience.org/library/papers/21881051 | PubMed |
| 2 | 26,551,060 | Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. | Nat Biotechnol | 2015 | https://conductscience.org/library/papers/26551060 | PubMed |
| 3 | 27,820,943 | CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. | Nature | 2016 | https://conductscience.org/library/papers/27820943 | PubMed |
| 4 | 21,321,359 | Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. | Blood | 2011 | https://conductscience.org/library/papers/21321359 | PubMed |
| 5 | 19,997,089 | Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. | Mol Ther | 2010 | https://conductscience.org/library/papers/19997089 | PubMed |
| 6 | 18,650,378 | In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18650378 | PubMed |
| 7 | 20,676,099 | Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. | Nat Genet | 2010 | https://conductscience.org/library/papers/20676099 | PubMed |
| 8 | 6,183,586 | 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. | N Engl J Med | 1982 | https://conductscience.org/library/papers/6183586 | PubMed |
| 9 | 12,391,330 | Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/12391330 | PubMed |
| 10 | 6,200,161 | Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? | Blood | 1984 | https://conductscience.org/library/papers/6200161 | PubMed |
| 11 | 28,956,530 | Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. | Elife | 2017 | https://conductscience.org/library/papers/28956530 | PubMed |
| 12 | 19,056,937 | Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. | Science | 2008 | https://conductscience.org/library/papers/19056937 | PubMed |
| 13 | 12,050,007 | Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. | Biophys Chem | 2002 | https://conductscience.org/library/papers/12050007 | PubMed |
| 14 | 24,597,865 | Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24597865 | PubMed |
| 15 | 23,939,622 | CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. | Nucleic Acids Res | 2013 | https://conductscience.org/library/papers/23939622 | PubMed |
| 16 | 28,330,619 | Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy. | Stem Cell Reports | 2017 | https://conductscience.org/library/papers/28330619 | PubMed |
| 17 | 9,734,950 | Granulocytosis causing sickle-cell crisis. | Lancet | 1998 | https://conductscience.org/library/papers/9734950 | PubMed |
| 18 | 30,282,642 | Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. | Blood Adv | 2018 | https://conductscience.org/library/papers/30282642 | PubMed |
| 19 | 28,895,851 | Gene Therapy Approaches to Hemoglobinopathies. | Hematol Oncol Clin North Am | 2017 | https://conductscience.org/library/papers/28895851 | PubMed |
| 20 | 29,892,062 | p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. | Nat Med | 2018 | https://conductscience.org/library/papers/29892062 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37,497,271 | The APC-EPCR-PAR1 axis in sickle cell disease. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37497271 | PubMed |
| 37,298,481 | Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37298481 | PubMed |
| 35,526,095 | Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β-hemoglobinopathies. | Mol Ther | 2022 | https://conductscience.org/library/papers/35526095 | PubMed |
| 34,766,559 | Molecular genetics of β-thalassemia: A narrative review. | Medicine (Baltimore) | 2021 | https://conductscience.org/library/papers/34766559 | PubMed |
| 34,522,846 | The EHA Research Roadmap: Anemias. | Hemasphere | 2021 | https://conductscience.org/library/papers/34522846 | PubMed |
| 34,284,828 | PTD-mediated delivery of α-globin chain into Κ-562 erythroleukemia cells and α-thalassemic (HBH) patients' RBCs ex vivo in the frame of Protein Replacement Therapy. | J Biol Res (Thessalon) | 2021 | https://conductscience.org/library/papers/34284828 | PubMed |
| 33,525,591 | Genome Editing for β-Hemoglobinopathies: Advances and Challenges. | J Clin Med | 2021 | https://conductscience.org/library/papers/33525591 | PubMed |
| 32,439,726 | 2'-O-methoxyethyl splice-switching oligos correct splicing from IVS2-745 β-thalassemia patient cells restoring HbA production and chain rebalance. | Haematologica | 2019 | https://conductscience.org/library/papers/32439726 | PubMed |
| 32,406,490 | Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies. | Hum Mol Genet | 2020 | https://conductscience.org/library/papers/32406490 | PubMed |
| 32,167,945 | Small molecule therapeutics to treat the β-globinopathies. | Curr Opin Hematol | 2020 | https://conductscience.org/library/papers/32167945 | PubMed |
| 31,705,806 | Adenovirus vectors in hematopoietic stem cell genome editing. | FEBS Lett | 2019 | https://conductscience.org/library/papers/31705806 | PubMed |
| 31,700,592 | Curing Hemoglobinopathies: Challenges and Advances of Conventional and New Gene Therapy Approaches. | Mediterr J Hematol Infect Dis | 2019 | https://conductscience.org/library/papers/31700592 | PubMed |
| 30,945,167 | Disruptive Technology: CRISPR/Cas-Based Tools and Approaches. | Mol Diagn Ther | 2019 | https://conductscience.org/library/papers/30945167 | PubMed |
| 30,945,166 | Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases. | Mol Diagn Ther | 2019 | https://conductscience.org/library/papers/30945166 | PubMed |
| 30,903,542 | Theranostics of Genetic Diseases. | Mol Diagn Ther | 2019 | https://conductscience.org/library/papers/30903542 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HBB | 3,043 | PubTator's text mining | https://conductscience.org/library/genes/3043 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30701409
GET https://conductscience.org/api/papers/v1/30701409/references?page=2